Related Experiment Video
Updated: Jun 23, 2025
08:12
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
5.5K
Relapse and Survival in Bladder Cancer Patients Undergoing microRNA-129 and microRNA-145 Assays
Mostafa M M ELfieky1, Mohamed Abd El Rahman2,3, Aysam M Fayed1,4
1Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Egypt.
Asian Pacific Journal of Cancer Prevention : APJCP
|June 25, 2024
Summary
MicroRNAs 129 and 145 show promise in diagnosing breast cancer (BC). While miR-145 correlates with urothelial carcinoma progression, miR-129 does not significantly impact BC patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Accurate indicators for tumor invasiveness are crucial for effective cancer management.
- MicroRNAs (miRNAs) are increasingly recognized for their roles in cancer development and progression.
Purpose of the Study:
- To investigate the diagnostic and prognostic roles of microRNAs 129 and 145 in breast cancer (BC).
- To assess the impact of these miRNAs on tumor progression and patient survival.
Main Methods:
- Real-time PCR was used to quantify miR-129 and miR-145 expression in 75 BC patients and 75 controls.
- Receiver Operating Characteristic (ROC) curves and Area Under the Curve (AUC) analyses were performed for diagnostic accuracy.
- Kaplan-Meier survival analysis and Cox regression models were employed to evaluate survival outcomes.
Main Results:
- Both miR-129 and miR-145 demonstrated significant expression differences in BC patients.
- miR-129 and miR-145 exhibited high diagnostic potential for BC with AUC values of 0.943 and 0.748, respectively.
- miR-145 showed a significant correlation with the progression of urothelial carcinoma, but miR-129 did not significantly affect progression-free survival or mortality in BC patients.
Conclusions:
- A miRNA signature involving miR-129 and miR-145 can aid in BC detection.
- These findings suggest potential for developing miRNA-based therapeutics for BC and identifying survival-associated miRNAs.
